Related Experiment Video
Updated: Feb 15, 2026

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti1, Daniele Fanale1, Lorena Incorvaia1
1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy.
Abstract:
In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leucocytes, macrophages, dendritic cells and mast cells, TILs are considered a selected population of T-cells with a higher specific immunological reactivity against tumor cells than the non-infiltrating lymphocytes. In this review we will discuss the promising role of TILs as biomarkers reflecting the immune response to the tumor, describing their potential ability to predict the prognosis and clinical outcome of immunotherapy in some solid tumors.
Insights
Tumor-infiltrating lymphocytes (TILs) are key players in anti-tumor immunity. This review highlights their potential as biomarkers for predicting immunotherapy outcomes in solid tumors.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Immunotherapy has emerged as a validated treatment for various cancers, including melanoma, NSCLC, and RCC.
- Cancer cells evade immune surveillance by utilizing immune checkpoint receptors to inhibit anti-tumor immune cells.
- Tumor-infiltrating lymphocytes (TILs) represent a specialized T-cell population with heightened anti-tumor reactivity.
Purpose of the Study:
- To review the role of TILs as biomarkers in cancer.
- To explore the predictive potential of TILs for immunotherapy prognosis and clinical outcomes in solid tumors.
Main Methods:
- Literature review of clinical studies and research on anti-tumor immunity.
- Analysis of the mechanisms by which cancer cells interact with immune cells.
- Examination of TILs as indicators of immune response and therapeutic efficacy.
Main Results:
- TILs are crucial for eliciting anti-tumor immunity.
- Immune checkpoints are exploited by tumors to suppress TIL activity.
- TILs show promise as predictive biomarkers for immunotherapy.
Conclusions:
- TILs are valuable biomarkers reflecting the immune response to tumors.
- Assessing TILs can help predict prognosis and clinical outcomes of immunotherapy.
- Further research into TILs can optimize cancer treatment strategies.
Related Concept Videos
Tumor Immunotherapy
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Tumor Microenvironment
Types of Building Stone
Igneous rocks are formed from the solidification of magma or lava. An example is granite, known for its durability and resistance to weathering, making it ideal for parts of...
Quarrying of Stone
One common method involves using a diamond belt saw to cut large blocks from the quarry face. These blocks can be about 50 feet long and 12 feet high. After the initial vertical cut, drilling is performed at the base of the...
Stone Masonry

